Energy News / Shareholders Foundation, Inc.

NASDAQ:HRTX Investor Notice: Lawsuit Alleges Securities Laws Violations by Heron Therapeutics, Inc.

Via: ReleaseWire

Updated 11:45 AM CDT, Wed, June 19,2019

A lawsuit was filed on behalf of investors in Heron Therapeutics, Inc. (NASDAQ: HRTX) shares over alleged securities laws violations.

San Diego, CA -- (SBWIRE) -- 06/19/2019 -- The Shareholders Foundation announces that an investor, who purchased shares of Heron Therapeutics, Inc. (NASDAQ: HRTX), filed a lawsuit over alleged violations of Federal Securities Laws by Heron Therapeutics, Inc..

Investors who purchased shares of Heron Therapeutics, Inc. (NASDAQ: HRTX) have certain options and for certain investors are short and strict deadlines running. Deadline: August 5, 2019. NASDAQ: HRTX investors should contact the Shareholders Foundation at or call +1(858) 779 - 1554.

San Diego, CA based Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. On October 31, 2018, Heron Therapeutics, Inc announced the submission of its New Drug Application ("NDA") for HTX-011 to the U.S. Food and Drug Administration ("FDA") for postoperative pain management.

On February 22, 2019, Heron Therapeutics, Inc announced its financial results for the fourth quarter and full year 2018. Heron Therapeutics, Inc. reported that its annual Total Revenue rose from $30.76 million in 2017 to $77.47 million in 2018 and that its Net Loss declined from $197.48 million in 2017 to $178.84 million in 2018. Heron Therapeutics, Inc also stated that the U.S. Food and Drug Administration (FDA) accepted the new drug application (NDA) for Heron's investigational agent, HTX-011, and has granted it a Priority Review designation. Heron Therapeutics, Inc also said that the FDA set a Prescription Drug User Fee Act (PDUFA) goal date of April 30, 2019 and indicated that it is not currently planning an advisory committee meeting to discuss this application.

Then, on May 1, 2019, Heron Therapeutics, Inc announced receipt of a Complete Response Letter ("CRL") from the FDA on April 30, 2019, regarding Heron's NDA for HTX-011 for the management of postoperative pain (the "May 2019 Press Release"). In the May 2019 announcement, Heron Therapeutics, Inc advised investors that "[t]he CRL stated that the FDA is unable to approve the NDA in its present form based on the need for additional CMC and non-clinical information."

The plaintiff claims that between October 31, 2018 and April 30, 2019, the Defendants made false and/or misleading statements and/or failed to disclose that Heron had failed to include adequate Chemistry, Manufacturing, and Controls ("CMC") and non-clinical information in its NDA for HTX-011, that the foregoing increased the likelihood that the FDA would not approve Heron's NDA for HTX-011, and that as a result, Heron's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Heron Therapeutics, Inc. (NASDAQ: HRTX) have certain options and should contact the Shareholders Foundation.

Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

For more information on this press release visit:

Media Relations Contact
Michael Daniels
Email: Click to Email Michael Daniels